Navigation Links
Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
Date:11/24/2008

esearcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited three books, and written four others, including the best-selling textbook, Essential Psychopharmacology, now in its third edition and the best-selling clinical manual, Essential Psychopharmacology Prescriber's Guide.

Dr. Sheehan has been a consultant to the World Health Organization, the World Federation of Societies of Biological Psychiatry, the International Academy for Biomedical and Drug Research, the US Food and Drug Administration, and a research grant reviewer for the National Institute for Mental Health (NIMH). Dr. Sheehan has been invited to give over 1600 lectures in 64 countries throughout the world on anxiety and mood disorders, psychopharmacology and biological psychiatry. He was elected as a member of the American College of Psychiatrists and is a Distinguished Fellow of the American Psychiatric Association.

    About Labopharm's Novel Trazodone Formulation and the Market for
    Antidepressants

One-half of patients being treated with antidepressants discontinue therapy within a year for reasons related to efficacy and/or tolerability, including delayed onset of therapeutic response, insomnia or sleep disturbance, agitation, exacerbation of anxiety, sexual dysfunction, weight gain and somnolence. Labopharm has developed a novel once-daily formulation of 150 mg and 300 mg of trazodone hydrochloride, a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rat
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 ... which have special functions of adjusting human body ... have won great popularity with a variety of ... health food in China reached RMB187.4 billion, up ... 22.1% during 2006-2013. , China's health product industry ...
(Date:9/17/2014)... MarijuanaStock.net, a cannabis business news ... a “Video” section that contains important news and ... marijuana industry made available in video format. With ... given access to numerous interviews, news clips, and ... the issues they face. , The adding ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A  recent ... of a 24-year-old man named Advait Thakur who had ... caused by degenerative disc disease. This disease led to ... his nerve roots and causing severe pain. Leading spine ... and how it can lead to such severe pain, ...
(Date:9/17/2014)... September 17, 2014 Fresh off their ... to announce its support of The Silver Tour, an ... of the many benefits of medical marijuana. , Florida ... first medical marijuana dispensary and treatment center, ... raising funds to launch a statewide radio campaign in ...
(Date:9/17/2014)... 17, 2014 U.S. News and ... the country, and three mesothelioma treatment centers made ... the mesothelioma law firm Baron and Budd ... University of Texas MD Anderson Cancer Center and ... publication. ( http://health.usnews.com/best-hospitals/rankings/cancer ) , U.S. News and ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:MarijuanaStock.net Adds Business News Video Section to Their Website 2Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 2Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 3Health News:Florida Buds Supports Silver Tour 2Health News:Three Mesothelioma Treatment Centers Make U.S. News and World Report’s List of Top Cancer Care Facilities, Baron and Budd Reports 2Health News:Three Mesothelioma Treatment Centers Make U.S. News and World Report’s List of Top Cancer Care Facilities, Baron and Budd Reports 3
... cancer, found in dogs, wolves and coyotes, can repair its ... according to a new study in the journal Science ... unusual process that helps the cancer survive by stealing tiny ... infected animal, to incorporate as its own. They say this ...
... Amanda Gardner HealthDay Reporter , THURSDAY, Jan. 20 ... very differently depending on what side of the Atlantic ... ("swine") flu still predominated in Britain, where 112 people have ... and some doctors report running out of vaccine, according to ...
... The American Institute of Ultrasound in Medicine (AIUM) announced ... Fetal Echocardiography. The program sets the standard for care ... AIUM guidelines aimed at fostering its safe and effective ... a way for healthcare providers to show that they ...
... notion that feeling good may be good for your health ... article published in Current Directions in Psychological Science , ... existing research on how positive emotions can influence health outcomes ... how we age, however, that determines the quality of our ...
... Journal on Addictions reveals that illicit use of ... American male weightlifters. Additionally, illicit HGH use in this ... performance-enhancing and classical drugs. HGH, once an expensive ... cheaply available for illicit users on the street. ...
... , WEDNESDAY, Jan. 19 (HealthDay News) -- Scientists studying ... critters become resistant to pesticides, and the finding could ... across the United States. "We are starting to ... researcher Omprakash Mittapalli, an assistant professor of entomology at ...
Cached Medicine News:Health News:Contagious cancer thrives in dogs by adopting host's genes 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 3Health News:AIUM announces ultrasound practice accreditation in fetal echocardiography 2Health News:Bedbugs Reveal Their Genetic Secrets in Lab Study 2Health News:Bedbugs Reveal Their Genetic Secrets in Lab Study 3
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014 Isis Pharmaceuticals, ... it has earned a $4 million milestone payment ... associated with the initiation of a Phase 3 ... resistant (MDR), gram-negative bacterial infections.  The Phase 3 ... evaluate the efficacy and safety of plazomicin compared ...
(Date:9/17/2014)... ALTO, Calif. , Sept. 17, 2014  Neuraltus ... the Company,s Phase 2 clinical program of NP001 for ... Lou Gehrig,s disease) are being highlighted today in ... the ALS Research Group , being held in ... to a  post hoc  analysis, administration of a high ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
McPherson curved tying forceps is long has curved shafts with tying platform 4 mm, serrated handle and polished finish. Overall length 110 mm....
McPherson straight tying forceps have straight shafts, tying platforms 4 mm, serrated handle, polished finish, overall length 85 mm....
Medicine Products: